The drug was approved by the agency in 2023 as a treatment for paroxysmal nocturnal hemoglobinuria ... in the U.K. The pulmonary arterial hypertension (PAH) drug, which also goes by the name ...

intracranial hypertension, unstable or deteriorating neurological status (Benamer & Bone, 2000; Ekseth et al., 1998). Supportive care is essential for these individuals, including optimizing ...

Objective To test the hypothesis that gouty arthritis (gout) is a risk factor for incidence of heart failure and for echocardiographic measures signifying subclinical heart failure. Design Post-hoc, ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ...